3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Rickets: new trials by email Literature Review of Rickets trials Research Report on Rickets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients Denosumab Inj 60 mg/ml, Placebo - Osteoporosis, Renal Osteodystrophy | Phase 2 | Terminated | Thomas Nickolas, MD MS | 8 | 2020-01-16 | 2024-07-25 |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism Etelcalcetide - Secondary Hyperparathyroidism | Phase 2 | Terminated | KAI Pharmaceuticals | 30 | 2012-03-01 | 2017-04-13 |
| Studies With 1,25-Dihydroxycholecalciferol 1,25-Dihydroxycholecalciferol - Hypocalcemia, Rickets | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 | 1976-03-01 | 2013-11-25 |
Chronic Kidney Disease-Mineral and Bone Disorder (2) · Hyperparathyroidism, Secondary (1) · Hypocalcemia (1) · Osteoporosis (1)
Avitaminosis (3) · Bone Diseases (3) · Bone Diseases, Metabolic (3) · Calcium Metabolism Disorders (3) · Deficiency Diseases (3) · Malnutrition (3) · Metabolic Diseases (3) · Musculoskeletal Diseases (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Vitamin D Deficiency (3) · Chronic Disease (2) · Disease Attributes (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2)
Calcitriol (1) · Denosumab (1) · etelcalcetide hydrochloride (1)
KAI Pharmaceuticals (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Thomas Nickolas, MD MS (1)
United States (2)
M D (1) · Stephen J Marx, MD (1) · Thomas Nickolas, MD, MS (1)